Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,471,950 papers from all fields of science
Search
Sign In
Create Free Account
NVP-LAF237
Known as:
NVP-LAF-237
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
vildagliptin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
Rebecca J. Mitchell
,
L. Hopcroft
,
+21 authors
G. Helgason
Journal of the National Cancer Institute
2018
Corpus ID: 3894405
Abstract Background Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically…
Expand
Review
2015
Review
2015
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
Philipp Holzer
,
K. Masuya
,
+13 authors
F. Gessier
Journal of medicinal chemistry
2015
Corpus ID: 38550159
As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the…
Expand
2015
2015
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma
R. Seggewiss-Bernhardt
,
R. Bargou
,
+10 authors
S. Iyer
Cancer
2015
Corpus ID: 7254145
NVP‐AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells. This…
Expand
Highly Cited
2010
Highly Cited
2010
89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922
W. Nagengast
,
M. D. de Korte
,
+11 authors
E. D. de Vries
Journal of Nuclear Medicine
2010
Corpus ID: 34732309
Angiogenesis is a critical step in tumor development, in which vascular endothelial growth factor (VEGF) is a key growth aspect…
Expand
Highly Cited
2010
Highly Cited
2010
Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction
L. Stingl
,
T. Stühmer
,
M. Chatterjee
,
M. Jensen
,
M. Flentje
,
C. Djuzenova
British Journal of Cancer
2010
Corpus ID: 9597815
Background:Heat-shock protein 90 (Hsp90) has a crucial role in both the stabilisation and regulation of various proteins…
Expand
2009
2009
The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo
M. Schwarzer
,
G. Faerber
,
+4 authors
T. Doenst
Basic Research in Cardiology
2009
Corpus ID: 31466467
Shifting substrate oxidation in heart muscle from fatty acids to glucose (substrate-switch) may improve contractile function in…
Expand
2008
2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
E. Weisberg
,
J. Roesel
,
+17 authors
J. Griffin
Blood
2008
Corpus ID: 22936649
An attractive target for therapeutic intervention is constitutively activated, mutant FLT3, which is expressed in a subpopulation…
Expand
Highly Cited
2003
Highly Cited
2003
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
E. B. Villhauer
,
J. Brinkman
,
+6 authors
T. Hughes
Journal of medicinal chemistry
2003
Corpus ID: 32652795
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and…
Expand
Highly Cited
2002
Highly Cited
2002
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
B. Ahrén
,
E. Simonsson
,
+9 authors
D. Holmes
Diabetes care
2002
Corpus ID: 15959568
OBJECTIVE Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the…
Expand
Highly Cited
2002
Highly Cited
2002
Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
M. Reimer
,
J. Holst
,
B. Ahrén
European journal of endocrinology
2002
Corpus ID: 23174474
OBJECTIVES Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE